Skip Navigation LinksHome > August 2010 - Volume 32 - Issue 6 > Sorafenib Plus Valproic Acid for Infant Spinal Glioblastoma
Journal of Pediatric Hematology/Oncology:
doi: 10.1097/MPH.0b013e3181d74702
Clinical and Laboratory Observations

Sorafenib Plus Valproic Acid for Infant Spinal Glioblastoma

Rokes, Christopher Alan MD*; Remke, Mark MD; Guha-Thakurta, Nandita MD; Witt, Olaf MD§; Korshunov, Andrey MD; Pfister, Stephan MD† §; Wolff, Johannes E. MD, PhD*

Collapse Box

Abstract

Spinal glioblastoma multiforme (GBM) is rare in children. New therapeutic options should be explored given the poor outcomes reported. We describe the case of an infant with spinal GBM whose condition worsened despite radiotherapy and chemotherapy. Immunohistochemical analysis of the tumor sample showed activation of the Raf-MEK-ERK pathway. Targeted pharmacologic therapy with sorafenib plus valproic acid led to decrease in the size of the tumor and improvement of symptoms. We conclude that regulation of the mitogen-activated protein kinase pathway using sorafenib plus valproic acid warrants further investigation for the management of childhood GBM.

© 2010 Lippincott Williams & Wilkins, Inc.

Login

Article Tools

Share

Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.

Connect With Us

Twitter
twitter.com/JPHOonline

For additional oncology content, visit LWW Oncology Journals on Facebook.